Longevity & Anti-Aging Biotech
Investment trends and scientific developments in anti-aging biotechnology, including regulatory risks and efficacy debates.
4 events tracked
Latest in Longevity & Anti-Aging Biotech· Oct 16
Major health systems are launching dedicated longevity medicine programs, signaling a shift of aging-focused treatments from specialized biotech toward mainstream clinical practice. This expansion reflects growing acceptance of healthspan-extension approaches within established healthcare infrastructure and suggests potential reallocation of capital and research priorities toward longevity-focused therapies. The integration of longevity medicine into traditional health systems could influence pharmaceutical development strategies and venture funding patterns in the aging-focused biotech sector, though the long-term clinical and economic impact remains to be demonstrated as these programs mature.
- Single source7 days ago
Major health systems launch longevity medicine programs as field gains traction
New York Times examines whether longevity medicine is entering mainstream adoption and investment.
The New York Times
- Single source12 days ago
CEO argues reviving prehistoric animals could advance human health and conservation
Colossal Biosciences leader contends that resurrecting vanished species may yield benefits for medicine, environmental protection, and biological research.
CNBC
- Single source23 days ago
Affluent individuals invest heavily in longevity treatments despite medical skepticism
Wealthy Americans spend up to $250,000 annually on longevity care; doctors weigh in on efficacy.
CNBC
- Single source25 days ago
Biotech investment in anti-aging races past scientific validation
Longevity science claims are outpacing evidence, raising questions about biotech and healthcare investment validity.
Al Jazeera